This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active
Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 ALVAL, PEA PME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
The TOTUM•63 mode of action clinical study has been officially launched, following the necessary authorizations from Health Canada and the CERUL2 and the first medical visit of the first subject
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.